Leading immuno-oncologist Norman Michael Greenberg joins Science Advisory Board of Machavert
We are very happy to welcome Dr. Norman Michael Greenberg to our Science Advisory Board (SAB). Norm will help us develop our immuno-oncology and drug delivery platform. Norm’s expertise and experience in immuno-oncology leading both academic research and drug development programs in biotech / pharma is of immense value. We all look forward to meet with Norm on our next SAB review meeting soon!
Dr. Greenberg is the Chief Scientific Officer and Senior Vice President at Atreca, a privately held biotechnology company developing novel therapeutics based on a deep understanding of the human immune response. He previously held positions including Senior Vice President for Translational Medicine at Checkmate Pharmaceuticals, Vice President of Global Research, Oncology, at MedImmune – AstraZeneca, and as Senior Director of Research, Oncology, at Pfizer. Dr. Greenberg has held academic appointments as a Full Member of the Clinical Research Division at the Fred Hutchinson Cancer Research Center in Seattle, and as a tenured Professor of Urology and Molecular and Cellular Biology at Baylor College of Medicine in Houston. Dr. Greenberg received a BSc in microbiology and immunology from the University of Toronto and a PhD in microbiology and immunology from the University of British Columbia. He performed postdoctoral research at Baylor College of Medicine in Houston.
Norm has already started helping us and had some lengthy discussions with our CSO, Neal Goodwin. “Machavert’s core technology has great potential due to both its own anti-cancer properties but also its potential to act as a drug delivery vehicle that together offer a multimodal mechanism of anti-cancer action. The excellent safety data so far suggest a great potential applicability of this platform in multiple therapeutic areas”, he said. We are very happy that Norm is going to support us in reaching our goal of translating Machavert’s platform into clinical reality for our patients!